vorsetuzumab mafodotin (SGN-75) / Pfizer - LARVOL DELTA

Answering Your Questions: Ocular Toxicity With Antibody–Drug Conjugates (Clinical Care Options) - "Sagar Lonial, MD: Initially, the trials excluded previous therapy with a BCMA-directed treatment. However, now many trials include separate cohorts to allow prior exposure to BCMA. Both the bispecific T-cell engager and the CAR T-cell trials are allowing this, presuming the previous BCMA-targeted therapy is belantamab mafodotin because it is approved by the FDA. There is some anecdotal experience of patients responding to a BCMA-targeted bispecific T-cell engager or bispecific antibody after belantamab mafodotin and BCMA expression is not lost as a consequence of progression. So, as of now, one BCMA therapy does not necessarily preclude another, but we await further data as the trials progress."

Interview

A Phase 1 dose-escalation trial of SGN-75 in CD70-positive non-hodgkin lymphoma or renal cell carcinoma (clinicaltrials.gov) - P1, N=113; Recruiting -> Active, not recruiting

Enrollment closed • Renal Cell Carcinoma